Drug profile · INN
iloprost
VENTAVIS
iloprost (VENTAVIS) is a prostanoid ip receptor agonist. Associated with Bayer Australia Ltd. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — iloprost
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- INHALATION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
iloprost (VENTAVIS) is a prostanoid ip receptor agonist. Associated with Bayer Australia Ltd. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Prostanoid IP receptor agonist
Primary target: Prostacyclin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is iloprost?
iloprost (VENTAVIS) is a prostanoid ip receptor agonist. Associated with Bayer Australia Ltd. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for iloprost?
VENTAVIS is a marketed brand name for iloprost. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of iloprost?
iloprost has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.